- Preface
- Acknowledgements
- Abbreviations
- List of contributors
- Glossary
- Case 1 Squamous cell carcinoma of unknown head and neck primary site
- Case 2 Nasopharyngeal carcinoma
- Case 3 Small cell lung cancer during pregnancy
- Case 4 Breast metastasis from non-small cell lung cancer
- Case 5 Lung cancer in non-smokers
- Case 6 Single brain metastasis from breast cancer
- Case 7 Breast cancer at a nuclear power station
- Case 8 Oesophagus
- Case 9 Stomach
- Case 10 Neuroendocrine tumour
- Case 11 A patient presenting with painless jaundice
- Case 12 Colon cancer
- Case 13 Rectal cancer
- Case 14 Anal cancer
- Case 15 Chromophobe renal cell carcinoma in an adult
- Case 16 Prostate cancer
- Case 17 Testicular cancer
- Case 18 Cervical cancer
- Case 19 Ovarian cancer
- Case 20 Cancer in a renal transplant recipient
- Case 21 Melanoma
- Case 22 Merkel cell carcinoma
- Case 23 Soft tissue sarcoma
- Case 24 Bone sarcoma
- Case 25 Brain tumour
- Case 26 Hodgkin lymphoma
- Case 27 Solitary plasmacytoma
- Case 28 Clinical trial
- Case 29 A jejunal tumour
- Case 30 The role of specialist palliative care
- List of cases by diagnosis
- List of cases by principal clinical features at presentation (case numbers in italics)
- List of cases by aetiological mechanism (case numbers in italics)
- Index
(p. 167) Testicular cancer
- Chapter:
- (p. 167) Testicular cancer
- Author(s):
Susanna Alexander
- DOI:
- 10.1093/med/9780199664535.003.0017
Testicular cancer has a high cure rate of approximately 95%. The typical presentation is in young adults aged 15-35 years. Orchiectomy is the standard of care and performed firstly unless there is life-threatening metastastic disease, and clinical diagnosis can be made by raised tumour markers. Postoperative treatment is based on the stage of the disease and histology (seminoma vs. non-seminoma). Residual masses can occur after chemotherapy in advanced clinical stages. These masses represent either residual disease or non-viable tissue. PET scan has in important role in predicting presence of viable disease in residual masses of in seminoma, especially if the mass is >3 cm. Because of the false negative results, PET has no established role in non-seminomatous residual disease.
Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.
Please subscribe or login to access full text content.
If you have purchased a print title that contains an access token, please see the token for information about how to register your code.
For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.
- Preface
- Acknowledgements
- Abbreviations
- List of contributors
- Glossary
- Case 1 Squamous cell carcinoma of unknown head and neck primary site
- Case 2 Nasopharyngeal carcinoma
- Case 3 Small cell lung cancer during pregnancy
- Case 4 Breast metastasis from non-small cell lung cancer
- Case 5 Lung cancer in non-smokers
- Case 6 Single brain metastasis from breast cancer
- Case 7 Breast cancer at a nuclear power station
- Case 8 Oesophagus
- Case 9 Stomach
- Case 10 Neuroendocrine tumour
- Case 11 A patient presenting with painless jaundice
- Case 12 Colon cancer
- Case 13 Rectal cancer
- Case 14 Anal cancer
- Case 15 Chromophobe renal cell carcinoma in an adult
- Case 16 Prostate cancer
- Case 17 Testicular cancer
- Case 18 Cervical cancer
- Case 19 Ovarian cancer
- Case 20 Cancer in a renal transplant recipient
- Case 21 Melanoma
- Case 22 Merkel cell carcinoma
- Case 23 Soft tissue sarcoma
- Case 24 Bone sarcoma
- Case 25 Brain tumour
- Case 26 Hodgkin lymphoma
- Case 27 Solitary plasmacytoma
- Case 28 Clinical trial
- Case 29 A jejunal tumour
- Case 30 The role of specialist palliative care
- List of cases by diagnosis
- List of cases by principal clinical features at presentation (case numbers in italics)
- List of cases by aetiological mechanism (case numbers in italics)
- Index